From 1 September 2026, the prescriber accreditation requirement for hepatitis B medicines under the PBS Section 100 (s100) Highly Specialised Drugs Program will be removed. As a result, all medical and authorised nurse practitioners will be able to prescribe hepatitis B antiviral treatment without additional specialist accreditation. ASHM is currently updating its website, education and resources to reflect this change.

Find out more

This World Liver Day, increase testing and treatment of hepatitis B and hepatitis C.  

Share the link to this page with others to keep them informed

With more than six million Australians affected by liver disease and more than 7,000 Australians dying each year from chronic liver disease, it is crucial to raise awareness of liver health.  

Did you know?  

  • Hepatitis B and hepatitis C are the primary causes of hepatocellular carcinoma (liver cancer) in Australia.   
  • Hepatitis B and hepatitis C can be managed in primary care, with effective treatments available for hepatitis B and an effective cure available for hepatitis C, meaning that liver cancer can be prevented!  

In recognition of World Liver Day, ASHM encourages its members to spread the word about liver health, including hepatitis B and hepatitis C. 

Find out more about how you can help to improve liver health outcomes by increasing testing, treatment, and ongoing management of hepatitis B and hepatitis C through attending ASHM training and reading ASHM resources.